---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265799"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:23:47.523063+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025

## Summary
- Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.
- BLA for atacicept in IgA nephropathy under Accelerated Approval submitted to FDA expected Q4 2025.
- ORIGIN 3 36-week results presented as late-breaking oral at ASN Kidney Week on Nov 6, 2025.
- PIONEER basket trial and ORIGIN Extend study actively enrolling; initial PIONEER data expected Q4 2025.
- Potential FDA approval and U.S. commercial launch of atacicept anticipated in 2026.

## SEC filing metadata
- accession: 0001193125-25-265799
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312525265799/0001193125-25-265799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312525265799/vera-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265799
- JSON: https://secwatch.observer/filing/0001193125-25-265799.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.